Figure 3.
Best response achieved in each patient and overall rates of response after ponatinib treatment of CP-CML patients with different BCR-ABL1 KD mutations. Individual mutations detected by MS in at least 2 patients are shown.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.